Every Form 4 that Adaptive Biotechnologies Corporation (ADPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADPT filings page.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an automatic share sale tied to equity compensation. On the RSU vesting date, 38,074 shares of common stock were sold to cover tax withholding obligations under a mandated “sell to cover” arrangement, rather than as a discretionary trade.
After this tax-related sale, Francis Lo directly owned 321,967 common shares. An additional 2,500 common shares were reported as indirectly owned through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp director Peter M. Neupert reported an acquisition of common stock through a grant or award. On March 4, 2026, he received 15,625 shares at a stated price of $0.0000 per share, bringing his directly owned holdings to 240,315 shares of common stock.
Adaptive Biotechnologies Corp director Robert Hershberg reported an award of common stock. On March 4, 2026, he acquired 15,625 shares of common stock through a grant with a stated price of $0.00 per share. Following this award, his direct holdings total 62,347 shares of common stock.
Adaptive Biotechnologies Corp reported that its Chief People Officer, Francis Lo, acquired 44,063 shares of common stock on March 4, 2026 through a stock grant at no cost, described as a grant, award, or other acquisition. Following this equity award, Lo directly holds 360,041 common shares. The filing also notes an additional 2,500 common shares held indirectly through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky received two awards of common stock on March 4, 2026. She acquired 59,375 shares in one grant and 62,500 shares in another, both at a reported price of $0.00 per share, increasing her directly held stake.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, Immune Medicine, Sharon Benzeno acquired 39,063 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. Following this award, Benzeno directly holds 335,854 common shares.
RUBINSTEIN JULIE reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp reported that President and COO Julie Rubinstein received a grant of 81,250 shares of Common Stock on March 4, 2026. The award was recorded at a price of $0.0000 per share, indicating it was granted for no cash consideration. Following this equity grant, Rubinstein’s directly owned holdings increased to 656,485 shares of Common Stock, reflecting a larger personal stake in the company.
Adaptive Biotechnologies Corp reported that Chief Scientific Officer Harlan S. Robins acquired shares of common stock through stock awards. On March 6, 2026, he received 709,220 shares at a price of $0.00 per share, and on March 4, 2026, he received 127,813 shares at $0.00 per share.
These awards relate to performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026. The company certified achievement of the performance goals on March 6, 2026, and the performance share units vested on that date, resulting in common stock delivery.
Adaptive Biotechnologies Corp reported that its Chief Financial Officer, Kyle Piskel, acquired 61,875 shares of common stock as a grant or award on March 4, 2026. The shares were recorded at a price of $0.00 per share, indicating they were not purchased on the open market but received as compensation. Following this transaction, Piskel directly owned 278,512 shares of Adaptive Biotechnologies common stock.
OWEN KATEY EINTERZ reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp director Katey Einterz Owen received an equity award of 15,625 shares of Common Stock on March 4, 2026. The shares were granted at a price of $0.00 per share, indicating a stock award rather than an open‑market purchase. Following this grant, her directly held Common Stock increased to 88,254 shares, reflecting her updated ownership position as a company director.
Adaptive Biotechnologies Corp director receives stock award
Adaptive Biotechnologies Corp director Michelle Renee Griffin acquired 15,625 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. After this transaction, she directly owns a total of 31,019 shares of the company’s common stock.
Adaptive Biotechnologies Corp reported that CEO and Chairman Chad M. Robins acquired common stock through equity awards. On March 6, 2026, he received 709,220 shares of common stock at a price of $0.00 per share, bringing his direct holdings to 2,771,280 shares after this transaction.
On March 4, 2026, he was also awarded 127,813 shares of common stock at $0.00 per share, resulting in 2,062,060 directly held shares after that earlier transaction. A related footnote explains that these awards stem from performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026, with the issuer certifying that performance goals were achieved and the units vesting on March 6, 2026.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported exercising stock options and selling shares. On the same day, she exercised options for 48,044 shares of common stock at $3.99 per share, then sold 48,044 common shares at a weighted average price of $15.30, with individual trades ranging from $15.11 to $15.54. After these transactions, she directly owned 15,394 common shares. The option was fully vested and exercisable, and the trades were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and related share sales. Over March 3–5, 2026, she exercised fully or partially vested stock options into common stock and sold 92,823 shares in open-market transactions at prices reported around the mid-teens per share.
The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, meaning they followed a prearranged schedule. After these transactions, Rubinstein held 575,235 shares of common stock directly. Reported sale prices are weighted averages of multiple trades, with ranges disclosed between $15.11 and $16.94 per share.
Adaptive Biotechnologies Corp’s Chief Scientific Officer, Harlan S. Robins, reported open-market sales of company common stock under a pre-established Rule 10b5-1 trading plan adopted on August 11, 2025.
He sold 10,000 shares on March 2, 2026 at a weighted average price of $15.72 per share and 14,233 shares on March 3, 2026 at a weighted average price of $16.52 per share. After these sales, he directly owned 1,155,291 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of an aggregate 524,998 shares of common stock in late February and early March 2026 under a Rule 10b5-1 trading plan adopted on August 11, 2025. The shares were sold in multiple transactions at weighted average prices, with sale prices ranging from $15.11 to $16.23 per share. Following these transactions, Robins directly holds 1,934,247 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Chief Financial Officer Kyle Piskel reported routine share transactions under a pre-set trading plan. On February 4, 2026, he exercised 2,145 stock options at $12.14 per share and acquired the same number of common shares.
That same day, he sold 2,145 common shares at $18.46 per share under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following these transactions, he directly owned 216,637 shares of common stock and 2,146 stock options. The options originally vested 25% on March 4, 2023, with the remainder vesting monthly thereafter.
Adaptive Biotechnologies’ Chief Scientific Officer, Harlan S. Robins, reported preset stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, he sold 34,668 shares of common stock at a weighted average price of $18.60, followed by a sale of 8,120 shares on February 3, 2026 at a weighted average price of $19.00.
The filing notes these trades were executed under a trading plan adopted on August 11, 2025, and that each reported price reflects multiple trades within stated ranges. After these transactions, Robins beneficially owned 1,179,524 shares of Adaptive Biotechnologies common stock directly.
Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported a planned stock sale. On February 2, 2026, he sold 124,998 shares of Common Stock at a weighted average price of $18.44 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on August 11, 2025.
After this sale, Robins beneficially owned 2,459,245 shares of Adaptive Biotechnologies Common Stock in direct form.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and a share sale in company stock. On January 12, 2026, Lo exercised several stock options, acquiring 36,650 shares at $7.80, 7,723 shares at $12.14, 21,002 shares at $8.46, and 14,215 shares at $3.99 per share. The same day, Lo sold 79,590 shares of common stock at $17.73 per share. After these transactions, Lo directly owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, and that the reported options are fully or time-vested according to their respective vesting schedules.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported an option exercise and share sale in company stock. On January 12, 2026, he exercised stock options for 4,290 shares of common stock at an exercise price of $12.14 per share, receiving 4,290 shares.
On the same date, he sold 4,290 shares of common stock at a price of $18 per share, leaving him with 216,637 shares of common stock held directly after the transactions. The filing notes these trades were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following the exercise, 4,291 stock options remained beneficially owned.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins sold 10,000 shares of common stock on January 6, 2026. The sale was reported at a weighted average price of $16.44 per share. According to the disclosure, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. After this sale, he beneficially owned 1,222,312 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies officer Francis Lo, the Chief People Officer, reported option exercises and a related stock sale for company shares. On December 22, 2025, Lo exercised stock options to acquire 1,100 shares at $7.80, 1,100 shares at $8.46, and 2,194 shares at $3.99 per share, then sold 4,394 shares of common stock at a weighted-average price of $17.50. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo directly beneficially owned 315,978 shares of common stock and held additional indirect ownership of 2,500 shares through spouse You Jin Lee, along with multiple remaining stock option positions.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported selling 124,998 shares of the company’s common stock on January 5, 2026 at a weighted average price of $15.59 per share. After this sale, he beneficially owned 2,584,243 shares directly.
The transaction was coded as an open market or private sale and was carried out under a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. The filing notes that the shares were sold in multiple trades at prices ranging from $15.31 to $15.96, and that detailed trade-by-trade information is available upon request.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an option exercise and matching share sale under a pre-set trading plan. On January 2, 2026, Lo exercised a stock option for 3,125 shares of common stock at an exercise price of $3.99 per share and then sold 3,125 shares of common stock at a weighted-average price of $16.08 per share. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025, which is designed to structure trades in advance. After these transactions, Lo beneficially owned 315,978 shares of Adaptive Biotechnologies common stock directly and 2,500 shares indirectly through spouse You Jin Lee, along with 104,856 stock options that remain beneficially owned.
Adaptive Biotechnologies Corp’s Chief People Officer reported stock option exercises and a share sale. On December 15, 2025, the officer exercised options to acquire a total of 97,022 shares of common stock at exercise prices of $7.8, $8.46, and $3.99 per share. On the same date, 113,890 shares were sold in an open-market transaction at a weighted-average price of $15.57, with individual sale prices ranging from $15.37 to $16.03, all under a Rule 10b5-1 trading plan adopted on September 15, 2025. Following these transactions, the reporting person directly beneficially owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse, and continued to hold multiple vested stock options.
Adaptive Biotechnologies director Robert Hershberg reported an open-market sale of company stock. On 12/10/2025, he sold 22,968 shares of Adaptive Biotechnologies common stock at a price of $16 per share.
Following this transaction, Hershberg now beneficially owns 46,722 shares of Adaptive Biotechnologies common stock, held directly. The filing identifies him as a director of the company and shows that the report was filed for a single reporting person.
Adaptive Biotechnologies (ADPT) reported insider transactions by its Chief Commercial Officer, Immune Medicine, Sharon Benzeno. On November 20–21, 2025, she executed multiple stock option exercises and related sales of common stock under a Rule 10b5-1 trading plan adopted on August 18, 2025.
She exercised options covering 133,032, 68,961, 834, 20,834, 49,480, 34,375, 119,809 and 83,145 shares at exercise prices between $3.99 and $12.14 per share, converting them into common stock. She then sold 297,925 shares at a weighted average price of $16.54 and 308,477 shares at a weighted average price of $16.91 in multiple transactions within stated price ranges.
Following these transactions, she directly beneficially owns 296,791 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp (ADPT) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO sold 238 shares of common stock at a price of $14.05 per share. After this transaction, the CFO beneficially owned 269,343 shares of Adaptive Biotechnologies common stock directly.
The company explains that this sale was made solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The transaction was carried out under the issuer’s equity incentive plan, which requires a mandatory "sell to cover" to satisfy tax obligations, so it was not a discretionary trade by the reporting person.
Adaptive Biotechnologies (ADPT) disclosed an insider transaction by its Chief Scientific Officer.
On 11/10/2025, Harlan S. Robins sold 10,000 shares of common stock at a weighted average price of $14.82, with trades ranging from $14.58 to $15.05, pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025. Following the sale, he beneficially owned 1,269,524 shares held directly.
Adaptive Biotechnologies (ADPT) insider activity: CEO and Chairman Chad M. Robins reported open-market sales of common stock executed under a Rule 10b5-1 trading plan adopted on August 11, 2025. On November 10, he sold 86,161 shares at a weighted average price of $14.73, followed by 1,237 shares at $14.57 on November 11, and 1,867 shares at $15.00 on November 12. After these transactions, he beneficially owned 2,869,975 shares directly. The prices reflect weighted averages across multiple trades within disclosed ranges.